HER2-RADiCAL Trial, Joint Lead Investigator

Activity: Other activity typesOther

Description

The HER2-RADiCAL Trial is a key part of the NCRI Breast Research Group (whch I chair) strategy to develop risk-adapted treatment for women with breast cancer. This NIHR HTA-funded study (£1.6M) will look at the de-intensification of treatment for women with breast cancer who have a complete response to pre-surgical chemotherapy. As part of the core leadership team of four clinicians/methodologists and the Surgical lead for the study, I will provide input into the design and delivery of the trial, as well as into the analysis and presentation of the results. This trial builds on previous work from the NCRI Breast Research Group, and has the potential to significantly change clinical practice in the treatment of breast cancer, while improving the quality of life for patients and bringing significant cost savings to the NHS.
Period20202027
Degree of RecognitionNational